Pulmonary Involvement of Acute Myeloid Leukemia Mimicking Transfusion-related Acute Lung Injury

Kentaro Ido¹, Yasutaka Aoyama¹, Joji Nagasaki², Shiro Koh¹, Hiroyoshi Ichihara¹, Hiroshi Harada¹, Kiyoshi Kawano¹, Yoshihiko Tani¹, Nobuki Matsuyama¹, Fumiya Hirayama¹, Masatoshi Kohsaki⁴, Shuji Takaku⁴ and Atsuko Mugitani¹

Abstract:
Transfusion-related acute lung injury (TRALI) is defined as a new episode of acute lung injury (ALI) occurring during transfusion or within 6 hours of transfusion completion. A 66-year-old man suffering from acute myeloid leukemia developed acute respiratory distress syndrome after platelet transfusion. TRALI was diagnosed clinically, but an autopsy showed leukemic cells in diffuse pulmonary edema. Anti-human neutrophil antigen (HNA)-3a antibodies were detected in the donor serum, and the HNA-3 genotype of the patient was identified as a/a. This case was considered to represent pulmonary involvement of acute myeloid leukemia, rather than TRALI. A revision of the definition of TRALI accounting for hematological malignancies should therefore be considered.

Key words: transfusion-related acute lung injury, acute myeloid leukemia, autopsy

(Intern Med 56: 2493-2496, 2017) (DOI: 10.2169/internalmedicine.8505-16)

Introduction

Transfusion-related acute lung injury (TRALI) is defined as a new episode of acute lung injury (ALI) that occurs during transfusion or within 6 hours of transfusion completion and is not temporally related to a competing etiology for ALI (1). The diagnosis of TRALI is based on clinical and radiographic findings and is not dependent on the results of laboratory tests or any proposed pathophysiological mechanisms. Inductively, TRALI is pathologically characterized by pulmonary edema with neutrophilic aggregates in the pulmonary microvasculature and the extravasation of neutrophils (2).

The pathogenesis of TRALI needs both a predisposition in the patient and mediators in the transfusate (3). Mediators in the transfusate include both antibody mediators and non-antibody mediators. The transfusion of leukocyte antibody-containing blood products increases the risk of TRALI 15-fold (4). Alloantibodies directed against human neutrophil antigen (HNA)-3a are related to fatal TRALI (5). The HNA-3 genotypes are a/a, a/b, and b/b.

Many reports have described the clinical diagnosis of TRALI in leukemia patients. However, none of those reports have been dissected. We herein report a case of acute pulmonary involvement of acute myeloid leukemia (AML) initially diagnosed with TRALI.

Case Report

A 66-year-old man was admitted to our hospital with hyperleukocytosis [white blood cell (WBC) count, 130.3×10⁹/L]. Chronic myelomonocytic leukemia (CMML)-1 had been diagnosed 6 weeks prior to this admission, based on the findings of 50.2% mature monocytes and 0.6% blasts in the bone marrow and the absence of a bcr-abl1 fusion gene. After admission, AML with myelodysplasia-related changes (MRC) was diagnosed, based on the findings of 5.2% ma-

¹Department of Hematology, Fuchu Hospital, Japan, ²Department of Hematology, Osaka City University Graduate School of Medicine, Japan, ³Department of Pathology, Fuchu Hospital, Japan, ⁴Japanese Red Cross Osaka Blood Center, Japan and ⁵Japanese Red Cross Kinki Block Blood Center, Japan

Received: November 6, 2016; Accepted: January 25, 2017; Advance Publication by J-STAGE: August 21, 2017
Correspondence to Dr. Kentaro Ido, m2049795@med.osaka-cu.ac.jp
Figure 1. Chronological chest X-rays. The lungs were normal on admission (A). Three days later, he developed dyspnea during platelet transfusion (B). The next day, he died (C).

Discussion

To our knowledge, this is the first reported autopsy case of clinically diagnosed TRALI in a leukemia patient. The lungs of the patient showed the pathological involvement of CD14-positive leukemic cells in diffuse pulmonary edema.
Figure 2. Histological sections of the lung from a patient suffering acute respiratory distress syndrome. Leukemic cells are seen infiltrating the interstitium and occupying middle-sized blood vessels in diffuse pulmonary edema (A). Some alveoli are involved, with the destruction of the normal lung architecture (B). Abnormal promonocytes and monoblasts show positive staining for cluster differentiation (CD) 14 (C). CD34 staining reveals obstruction of almost all pulmonary capillaries (D).

Figure 3. Detection of anti-HNA-3a antibodies in the donor serum by a granulocyte immune fluorescence test (GIFT) (A) and granulocyte agglutination test (GAT) (B). A tendency to react to the HNA-3 genotype a/a is evident.
Anti-HNA-3a antibodies were detected in donor serum, and the HNA-3 genotype of the patient was a/a.

TRALI was diagnosed clinically, but an autopsy revealed leukemic cells in diffuse pulmonary edema. This case was therefore considered to represent pulmonary involvement of AML rather than TRALI. Admittedly, we cannot rule out TRALI entirely, as the criteria for TRALI do not include any histological findings, and the exclusive risk factors for TRALI do not include hematological malignancies (1). However, all clinical syndromes should be resolved on the basis of the pathological description of etiology. In this case, leukemic cells overwhelmed the lungs, while neither neutrophilic aggregates in the pulmonary microvasculature nor extravasation of neutrophils, as histological characteristics of TRALI, were identified. The fact that pulmonary involvement of AML with hyperleukocytosis causes ARDS is well established (11, 12). Indeed, it is difficult to distinguish between pulmonary involvement of AML and TRALI precisely because leukemic cells occasionally behave like neutrophils in TRALI. As such, revising the definition of TRALI to take hematological malignancies into consideration seems warranted.

Anti-HNA-3a antibodies were detected in donor serum and the patient showed an HNA-3 genotype of a/a. In addition, dyspnea developed during the infusion of a platelet transfusate containing anti-HNA-3a antibodies. These lines of evidence indirectly suggested TRALI. Although patients suffering from hematological malignancies are considered to be at risk of developing clinical TRALI (13), how leukemic cells behave when anti-leukocyte alloantibodies are transfused and which stage of leukocyte differentiation HNA-3 is expressed at remain unclear, because these issues have yet to be investigated pathologically.

TRALI has been investigated in vivo under conditions of normal neutrophil function. In the present case, neutropenia and hyperleukocytosis of CD14-positive leukemic cells were present. However, these facts do not exclude TRALI, because neutrophil depletion does not prevent mice from developing TRALI induced by anti-HNA-3a antibodies, despite alleviating the severity of lung injury (14).

This case was considered to represent pulmonary involvement of AML rather than TRALI. A revision of the definition of TRALI accounting for hematological malignancies should be considered. To reduce the risk of TRALI, plasma-removed platelet concentrate (15) and male-only fresh-frozen plasma (16, 17) should be used in the future.

The authors state that they have no Conflict of Interest (COI).

Acknowledgement

We thank Eichi Morii and Masaharu Kohara (Department of Pathology, Osaka University Graduate School of Medicine) for valuable help in performing the CD14 staining.

References

1. Kleinman S, Caulfield T, Chan P, et al. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion 44: 1774-1789, 2004.
2. Cherry T, Steciuk M, Reddy VV, Marques MB. Transfusion-related acute lung injury: past, present, and future. Am J Clin Pathol 129: 287-297, 2008.
3. Vlaar AP, Juffermans NP. Transfusion-related acute lung injury: a clinical review. Lancet 382: 984-994, 2013.
4. Middelburg RA, van Stein D, Briet E, van der Born JG. The role of donor antibodies in the pathogenesis of transfusion-related acute lung injury: a systematic review. Transfusion 48: 2167-2176, 2008.
5. Reil A, Keller-Stanislawski B, Günay S, Bux J. Specificities of leucocyte alloantibodies in transfusion-related acute lung injury and results of leucocyte antibody screening of blood donors. Vox Sang 95: 313-317, 2008.
6. Japanese Ministry of Health and Welfare. Guideline for the Use of Blood Products. revised edition 2012.
7. Ferguson ND, Fan E, Camporota L, et al. The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material. Intensive Care Med 38: 1573-1582, 2012.
8. Verheugt FW, von dem Borne AE, Décary F, Engelfriet CP. The detection of granulocyte alloantibodies with an indirect immunofluorescence test. Br J Haematol 56: 533-544, 1977.
9. Reil A, Wesche J, Greinacher A, Bux J. Geno- and phenotyping and immunogenicity of HNA-3. Transfusion 51: 18-24, 2011.
10. Yasui K, Tanaka M, Hayashi T, et al. High-resolution melting analysis as an alternative method for human neutrophil antigen genotyping. Immunohematology 31: 7-13, 2015.
11. Ganzel C, Becker J, Mintz PD, Lazarus HM, Rowe JM. Hyperleukocytosis, leukostasis and leukapheresis: practice management. Blood Rev 26: 117-122, 2012.
12. Röllig C, Ehninger G. How I treat hyperleukocytosis in acute myeloid leukemia. Blood 125: 3246-3252, 2015.
13. Silliman CC, Boshkov LK, Medhzidakehashi Z, et al. Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood 101: 454-462, 2003.
14. Bayat B, Tjahjono Y, Sydovsky A, et al. Anti-human neutrophil antigen-3a induced transfusion-related acute lung injury in mice by direct disturbance of lung endothelial cells. Arterioscler Thromb Vasc Biol 33: 2538-2548, 2013.
15. Azuma H, Hirayama J, Akino M, et al. Reduction in adverse reactions to platelets by the removal of plasma supernatant and resuspension in a new additive solution (M-sol). Transfusion 49: 214-218, 2009.
16. Eder AF, Herron RM Jr, Strupp A, et al. Effective reduction of transfusion-related acute lung injury risk with male-predominant plasma strategy in the American Red Cross (2006-2008). Transfusion 50: 1732-1742, 2010.
17. Wiersum-Osselton JC, Middelburg RA, Beckers EA, et al. Male-only fresh-frozen plasma for transfusion-related acute lung injury prevention: before-and-after comparative cohort study. Transfusion 51: 1278-1283, 2011.